Verdad Advisers’s Acrivon Therapeutics ACRV Stock Holding History

Verdad Advisers’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.8K	Buy	+15,054	New	+$25.6K	0.03%	206

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's ACRV Position: Q2 2026 in Review

Verdad Advisers opened a new position in Acrivon Therapeutics (ACRV) in Q2 2026: 15,054 shares worth $26.8K. The stake represents 0.03% of the portfolio and ranks #206 among its holdings.

46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Verdad Advisers held 15,054 shares of Acrivon Therapeutics worth $26.8K as of Q2 2026.
Acrivon Therapeutics was a new Verdad Advisers position in Q2 2026.
Acrivon Therapeutics made up 0.03% of Verdad Advisers's portfolio in Q2 2026, its #206 holding.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.